VANCOUVER, March 12, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California.Â InMed’s presentation at the conference is currently scheduled for Tuesday, March 13th, at 3:30 PM, PST.
“The ROTH Conference is one of the largest emerging growth and healthcare-focused events in the United States, and it does a wonderful job introducing small and mid-cap companies to investors who are focused on companies with high-growth potential,” commented Mr. Adams.Â “InMed Pharmaceuticals is honored to have been asked to present to this assembly of investors who represent significant resources in the healthcare space.”
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
About ROTH Capital Conference:
ROTH Capital Partners 30th Annual Conference is one of the largest of its kind in the U.S. Following the success of previous years’ events, the ROTH Conference, with close to 500 participating companies and over 4,000 investor attendees, will feature presentations from hundreds of public and private companies in a variety of sectors including Healthcare. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a ‘must attend’ event for anyone working in the small and mid-cap space. ROTH combines company presentations, Q&A sessions and management one-on-one meetings so that institutional investors can have an in-depth look at company senior management and issues affecting the growth of the presenting companies.
ROTH is an investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this market. Headquartered in Newport Beach, CA, ROTH has regional offices in Boston, Chicago, Larkspur, Los Angeles, New York, San Diego and Hong Kong.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.